GGGG

[GGGG @iBigMeh]

@ozzy_livin hmm is the math still valid this time

[Ronaldo Putera @ronaldoputera]

Already predicting this

This is their gameplay

[Ozzy @ozzy_livin]

TODAY → Nov 1st

Last chance to acquire LIFETIME access to indicators at https://t.co/NOk7KEvLKB

#Tradingview is transitioning invite-only 🔒 scripts to monthly subscriptions through their own Tradingview Marketplace

What this means :

🔸 Those who have already acquired LIFETIME access will continue to have access

🔸 Starting Nov 1st LIFETIME access ends

🔸 Indicators will only be available on Tradingview Marketplace offered as a monthly subscription

[Andrés Gutiérrez | Inversión y Bolsa @aguti00]

Solo 15 acciones de todo el S&P500 cumplen con esto:

* Revenue Growth (3 años): > 10%
* ROIC (Retorno sobre el capital invertido): > 15%
* P/E Ratio (PER): < 25
* Market Cap: > $2B (Mid, Large o Mega cap)

Calidad a precio razonable.

[value @ValueReporter]

As I said, history rarely repeats itself. But this case of Forma is really interesting the context of $WVE:
- Forma - $20 IPO, big run to $40+, raising after the run, 18+ months of downward movement (WVE had Dec 2025 offering at highs)
- assets in different areas (Novo only wanted sickle cell drug, so Forma offloaded other stuff for cheap during negotiation months).has a similar WVE situation with DMD/Huntington now
- RA Capital with around 20% of stake in both

I think $WVE got their low-ball offer recently, maybe 1-2 weeks after redomiciliation. It's a tough pill to swallow and the board is trying to act from the position of strength. They have some aces in the pocket, but not much. If the bidder is Novo, they are scrappy bastards.